Annals of Emergency Medicine
Volume 49, Issue 2 , Pages 172-177 , February 2007

Prescription Naloxone: A Novel Approach to Heroin Overdose Prevention

  • Karl A. Sporer, MD

      Affiliations

    • University of California, San Francisco, Department of Medicine, Section of Emergency Medicine, and the Treatment Research Center, the Urban Health Program, RTI International and the University of California, San Francisco, CA
    • Corresponding Author InformationAddress for correspondence: Karl Sporer, MD, Emergency Services, Room 1E21, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110; 415-206-5749, fax 415-206-5818
    • ,
  • Alex H. Kral, PhD

      Affiliations

    • Department of Family and Community Medicine, San Francisco, CA

Received 7 February 2006 ,Revised 25 April 2006 ,Accepted 23 May 2006.

References 

  1. Oxman G, Kowalski S, Drapela L, et al. Heroin overdose deaths: Multnomah County, Oregon, 1993-1999. MMWR Morb Mortal Wkly Rep. 2000;49:633–636
  2. Solet D, Hagan H, Nakagawara J, et al. Unintential opiate overdose deaths: King County, Washington, 1990-1999. MMWR Morb Mortal Wkly Rep. 2000;49:636–640
  3. Gerostamoulos J, Staikos V, Drummer OH. Heroin-related deaths in Victoria: a review of cases for 1997 and 1998. Drug Alcohol Depend. 2001;61:123–127
  4. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80:189–200
  5. Warner-Smith M, Darke S, Lynskey M, et al. Heroin overdose: causes and consequences. Addiction. 2001;96:1113–1125
  6. Hulse GK, English DR, Milne E, et al. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–229
  7. Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. 2003;80:291–301
  8. Drug Abuse Warning Network. Emergency department trends from DAWN: final estimates 1995-2002 [Drug Abuse Warning Network Web site]. Available at: http://dawninfo.samhsa.gov/old_dawn/pubs_94_02/edpubs/2002final. Accessed March 8, 2006.
  9. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215–232
  10. Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97:963–967
  11. Darke S, Sims J, McDonald S, et al. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95:687–695
  12. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130:584–590
  13. Way EL, Kemp JW, Young JM, et al. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther. 1960;129:144–154
  14. Oldendorf WH, Hyman S, Braun L, et al. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972;178:984–986
  15. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961–972
  16. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998;316:426–428
  17. Ochoa KC, Davidson PJ, Evans JL, et al. Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend. 2005;80:297–302
  18. Tagliaro F, De Battisti Z, Smith FP, et al. Death from heroin overdose: findings from hair analysis. Lancet. 1998;351:1923–1925
  19. Darke S, Hall W, Kaye S, et al. Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction. 2002;97:977–984
  20. Darke S, Ross J, Teesson M, et al. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Addiction. 2003;98:1129–1135
  21. Burns JM, Martyres RF, Clode D, et al. Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. Med J Aust. 2004;181(7 suppl):S25–S28
  22. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help?. escalating “doctor shopping” by young heroin users before fatal overdose. Med J Aust. 2004;180:211–214
  23. Seal K, Kral A, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay area, 1998-1999. Am J Public Health. 2001;91:1842–1846
  24. O’Driscoll PT, McGough J, Hagan H, et al. Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health. 2001;91:984–987
  25. Galea S, Ahern J, Tardiff K, et al. Racial/ethnic disparities in overdose mortality trends in New York City, 1990-1998. J Urban Health. 2003;80:201–211
  26. Galea S, Ahern J, Vlahov D, et al. Income distribution and risk of fatal drug overdose in New York City neighborhoods. Drug Alcohol Depend. 2003;70:139–148
  27. Latkin CA, Hua W, Tobin K. Social network correlates of self-reported non-fatal overdose. Drug Alcohol Depend. 2004;73:61–67
  28. Neale J, Robertson M. Recent life problems and non-fatal overdose among heroin users entering treatment. Addiction. 2005;100:168–175
  29. Miotto K, McCann MJ, Rawson RA, et al. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend. 1997;45:131–134
  30. Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450–460
  31. Oliver P, Horspool M, Keen J. Fatal opiate overdose following regimen changes in naltrexone treatment. Addiction. 2005;100:560–561
  32. Sporer KA. Strategies for preventing heroin overdose. BMJ. 2003;326:442–444
  33. Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. Med J Aust. 1996;164:204–207
  34. Davidson PJ, McLean RL, Kral AH, et al. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health. 2003;80:261–273
  35. Davidson PJ, Ochoa KC, Hahn JA, et al. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction. 2002;97:1511–1516
  36. Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. Addiction. 2005;100:397–404
  37. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82:303–311
  38. Strang J, Best D, Man L, et al. Peer-initiated overdose resuscitation: fellow drug users could be mobilised to implement resuscitation. Int J Drug Policy. 2000;11:437–445
  39. Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users. Int J Epidemiol. 1993;22:273–277
  40. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7:249–256
  41. Caplehorn JR, Dalton MS, Haldar F, et al. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31:177–196
  42. van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addict Behav. 1999;24:559–563
  43. Stewart D, Gossop M, Marsden J. Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). J Subst Abuse Treat. 2002;22:1–9
  44. Bartu A, Freeman NC, Gawthorne GS, et al. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction. 2004;99:53–60
  45. Brugal MT, Domingo-Salvany A, Puig R, et al. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100:981–989
  46. Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat. 2002;23:87–92
  47. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43:580–584
  48. Gueye PN, Megarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction. 2002;97:1295–1304
  49. Degenhardt LJ, Conroy E, Gilmour S, et al. The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Med J Aust. 2005;182:20–23
  50. Degenhardt L, Day C, Dietze P, et al. Effects of a sustained heroin shortage in three Australian states. Addiction. 2005;100:908–920
  51. Bammer G. What can a trial contribute to the debate about supervised injecting rooms?. Aust N Z J Public Health. 2000;24:214–215
  52. Yamey G. UN condemns Australian plans for “safe injecting rooms”. BMJ (Clin Res Ed). 2000;320:667
  53. Dietze P, Jolley D, Cvetkovski S. Patterns and characteristics of ambulance attendance at heroin overdose at a local-area level in Melbourne, Australia: implications for service provision. J Urban Health. 2003;80:248–260
  54. Tobin KE, Latkin CA. The relationship between depressive symptoms and nonfatal overdose among a sample of drug users in Baltimore, Maryland. J Urban Health. 2003;80:220–229
  55. Hall WD. How can we reduce heroin “overdose” deaths?. Med J Aust. 1996;164:197–198
  56. Strang J, Darke S, Hall W, et al. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312:1435–1436
  57. Darke S, Hall W. The distribution of naloxone to heroin users. Addiction. 1997;92:1195–1199
  58. Abbasi K. Deaths from heroin overdose are preventable. BMJ. 1998;316:331
  59. Hall W, Zador D. Challenge of reducing drug-related deaths. Lancet. 2000;356:7–8
  60. Lenton SR, Hargreaves KM. Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose?. Med J Aust. 2000;173:260–263
  61. Burris S, Norland J, Edlin B. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy. 2001;12:237–248
  62. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2005;100:1823–1831
  63. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;895–896
  64. Simini B. Naloxone supplied to Italian heroin addicts. Lancet. 1998;352:967
  65. Sergeev B, Karpets A, Sarang A, et al. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. J Urban Health. 2003;80:212–219
  66. Coffin PO, Fuller C, Vadnai L, et al. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80:288–290
  67. Bigg D. Data on take home naloxone are unclear but not condemnatory. BMJ. 2002;324:678
  68. Seal KH, Thawley R, Hammond JP, et al. Providing naloxone and training to IDUs can save lives. 2003;Paper presented at: American Public Health Association annual meeting, November 15-19, San Francisco, CA
  69. Galea S, Worthington N, Piper TM, et al. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav. 2006;31:907–912
  70. Chamberlain J, Klein B. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12:650–660
  71. Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005;22:612–616
  72. Sporer KA, Firestone J, Isaacs SM. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med. 1996;3:660–667
  73. Kelly AM, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24–27
  74. Wanger K, Brough L, Macmillan I, et al. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998;5:293–299
  75. Mountain D. Take home naloxone for opiate addicts: big conclusions are drawn from little evidence. BMJ. 2001;323:934
  76. Mirakbari SM, Innes GD, Christenson J, et al. Do co-intoxicants increase adverse event rates in the first 24 hours in patients resuscitated from acute opioid overdose?. J Toxicol Clin Toxicol. 2003;41:947–953
  77. Osterwalder JJ. Naloxone for intoxications with intravenous heroin and heroin mixtures: harmless or hazardous?. a prospective clinical study. J Toxicol Clin Toxicol. 1996;34:409–416
  78. Buajordet I, Naess AC, Jacobsen D, et al. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11:19–23
  79. Daly FFS, Fatovich DM, Bartu A, et al. A prospective study of opioid overdose. Emerg Med. 2002;14(suppl):A32
  80. Dietze P, Cantwell K, Burgess S. Bystander resuscitation attempts at heroin overdose: does it improve outcomes?. Drug Alcohol Depend. 2002;67:213–218

 Supervising editor: Richard D. Dart, MD, PhDFunding and support: The authors report this study did not receive any outside funding or support but discloses that KAS receives compensation for AED medical direction from American Health and Safety Training, Inc.Reprints not available from the authors.

PII: S0196-0644(06)00796-7

doi: 10.1016/j.annemergmed.2006.05.025

Annals of Emergency Medicine
Volume 49, Issue 2 , Pages 172-177 , February 2007

Article Tools

* Image Usage & Resolution